Synopsis
Synopsis
0
CEP/COS
0
KDMF
0
VMF
0
Australia
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. Dried Aluminum Hydroxide Gel
2. Aluminum;trihydroxide
3. Aluminium Hydroxide Gel, Dried
4. Dried Aluminium Hydroxide
5. Aluminum Hydroxide, Dried
6. Aluminium Hydroxide, Dried
7. Aluminum Hydroxide Gel, Dried
8. Nsc-664400
9. Aluminum Hydrate
10. Aluminum Hyroxide
11. Aluminium Trihydroxide
12. Hydroxyde D' Aluminium
13. Algeldrate Anhydrous
14. Aluminum (as Hydroxide)
15. Aluminum Hydroxide [ii]
16. Aluminum Hydroxide [mi]
17. Chembl1200706
18. Dtxsid2036405
19. Niosh/bd0708000
20. Aluminum Hydroxide [inci]
21. Di-mu-hydroxytetrahydroxydialuminum
22. Aluminum Hydroxide [vandf]
23. Aluminium Hydroxide[who-ip]
24. Aluminum Hydroxide [mart.]
25. Aluminum Hydroxide Gel,dried
26. Aluminium Hydroxide Dried Gel
27. Af-260
28. Aluminium Hydroxide [who-dd]
29. Akos015904617
30. Aluminum, Di-mu-hydroxytetrahydroxydi-
31. Db06723
32. Aluminum Hydroxide [orange Book]
33. Aluminii Hydroxidum[who-ip Latin]
34. Aluminum (as Hydroxide) [vandf]
35. Aluminum Hydroxide [usp Impurity]
36. Aluminum Hydroxide, Dried [hsdb]
37. As04 Component Aluminum Hydroxide
38. Aluminum Hydroxide Gel, Dried [ii]
39. Foamcoat Component Aluminum Hydroxide
40. Foamicon Component Aluminum Hydroxide
41. Gaviscon Component Aluminum Hydroxide
42. Aluminum Hydroxide Gel,dried [vandf]
43. Bd07080000
44. Dried Aluminum Hydroxide Gel [usp-rs]
45. Aluminum Hydroxide Component Of Foamcoat
46. Aluminum Hydroxide Component Of Foamicon
47. Aluminum Hydroxide Component Of Gaviscon
48. Aluminium Hydroxide Gel, Dried [who-dd]
49. Aluminum Hydroxide, Dried [usp Impurity]
50. Q407125
51. J-014205
52. 8012-63-3
| Molecular Weight | 78.004 g/mol |
|---|---|
| Molecular Formula | AlH3O3 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 0 |
| Exact Mass | 77.9897574 g/mol |
| Monoisotopic Mass | 77.9897574 g/mol |
| Topological Polar Surface Area | 3 Ų |
| Heavy Atom Count | 4 |
| Formal Charge | 0 |
| Complexity | 0 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 4 |
For relief of heartburn and acid indigestion.
Gastric-peptic disease occurs as a result of an imbalance between protective factors, such as mucus, bicarbonate, and prostaglandin secretion, and aggressive factors, such as hydrochloric acid, pepsin, and Helicobacter pylori (H. pylori). Antacids work by restoring acid-base balance, attenuating the pepsin activity and increasing bicarbonate and prostaglandin secretion.
Absorption
Approximately 17-30% of the aluminum chloride formed is absorbed.
Route of Elimination
Absorbed aluminum chloride is rapidly eliminated by the kidneys in patients with normal renal function.
Not metabolized.
Aluminum hydroxide is a basic inorganic salt that acts by neutralizing hydrochloric acid in gastric secretions. Aluminum hydroxide is slowly solubilized in the stomach and reacts with hydrochloric acid to form aluminum chloride and water. It also inhibits the action of pepsin by increasing the pH and via adsorption. Cytoprotective effects may occur through increases in bicarbonate ion (HCO3-) and prostaglandins.
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
The funding will support the development of AD04 (aluminim hydroxide), a small molecule for Alzheimer's disease.
Lead Product(s): Aluminium Hydroxide,Inapplicable
Therapeutic Area: Neurology Brand Name: AD04
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: National Institute on Aging
Deal Size: $2.5 million Upfront Cash: Undisclosed
Deal Type: Funding September 26, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Aluminium Hydroxide,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : National Institute on Aging
Deal Size : $2.5 million
Deal Type : Funding
Advantage Therapeutics Receives $2.5M NIH Grant for Alzheimer’s Drug AD04® Development
Details : The funding will support the development of AD04 (aluminim hydroxide), a small molecule for Alzheimer's disease.
Product Name : AD04
Product Type : Miscellaneous
Upfront Cash : Undisclosed
September 26, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
ANK-101 is an anchored drug complex composed of interleukin-12 (IL-12) linked to aluminum hydroxide. It is being evaluated for the treatment of solid tumors.
Lead Product(s): ANK-101,Aluminium Hydroxide
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Protein
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 05, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : ANK-101,Aluminium Hydroxide
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Ankyra Therapeutics Doses First Visceral Tumor Patient in ANCHOR Trial
Details : ANK-101 is an anchored drug complex composed of interleukin-12 (IL-12) linked to aluminum hydroxide. It is being evaluated for the treatment of solid tumors.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
November 05, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
AD04 is a new class of therapeutic for mild Alzheimer’s disease that exhibits durable multifaceted effects, including both immediate symptomatic relief and long-term disease-modification.
Lead Product(s): Aluminium Hydroxide,Inapplicable
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 30, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Aluminium Hydroxide,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
ADvantage Therapeutics Announces Breakthrough Findings for AD04TM in Alzheimer's Disease
Details : AD04 is a new class of therapeutic for mild Alzheimer’s disease that exhibits durable multifaceted effects, including both immediate symptomatic relief and long-term disease-modification.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 30, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
ANK-101 is an anchored drug complex composed of interleukin-12 (IL-12) linked to aluminum hydroxide. It is being evaluated for the treatment of solid tumors.
Lead Product(s): ANK-101,Aluminium Hydroxide
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Protein
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 05, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : ANK-101,Aluminium Hydroxide
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Ankyra Doses First Patient in Phase 1 Trial of ANK-101 for Solid Tumors
Details : ANK-101 is an anchored drug complex composed of interleukin-12 (IL-12) linked to aluminum hydroxide. It is being evaluated for the treatment of solid tumors.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
March 05, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
AD04 is a novel immunotherapy for mild alzheimer’s disease. The compound has been used as an adjuvant in human and animal vaccination programs. It has demonstrated significantly slower decline in hippocampal volume as a biomarker.
Lead Product(s): Aluminium Hydroxide,Inapplicable
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 27, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Aluminium Hydroxide,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AD04 is a novel immunotherapy for mild alzheimer’s disease. The compound has been used as an adjuvant in human and animal vaccination programs. It has demonstrated significantly slower decline in hippocampal volume as a biomarker.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 27, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
AD04 (alhydrogel) is a novel immunotherapy for early alzheimer’s disease. The compound has been used as an adjuvant in human and animal vaccination programs. It has demonstrated significantly slower decline in hippocampal volume as a biomarker.
Lead Product(s): Aluminium Hydroxide,Inapplicable
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 20, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Aluminium Hydroxide,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
ADvantage Therapeutics Secures Approvals for Clinical Trial of AD04 in Alzheimer’s Disease Treat...
Details : AD04 (alhydrogel) is a novel immunotherapy for early alzheimer’s disease. The compound has been used as an adjuvant in human and animal vaccination programs. It has demonstrated significantly slower decline in hippocampal volume as a biomarker.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 20, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
AD04™ (alhydrogel) is a novel immunotherapy for mild Alzheimer’s Disease under the Innovative Licensing and Access Pathway (ILAP). AD04™ also showed slower decline in hippocampal volume as a biomarker.
Lead Product(s): Aluminium Hydroxide,Inapplicable
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 05, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Aluminium Hydroxide,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AD04™ (alhydrogel) is a novel immunotherapy for mild Alzheimer’s Disease under the Innovative Licensing and Access Pathway (ILAP). AD04™ also showed slower decline in hippocampal volume as a biomarker.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 05, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
AD04™ (alhydrogel) is a novel immunotherapy for early alzheimer’s disease. The compound has been used as an adjuvant in human and animal vaccination programs. It has demonstrated significantly slower decline in hippocampal volume as a biomarker.
Lead Product(s): Aluminium Hydroxide,Inapplicable
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 15, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Aluminium Hydroxide,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AD04™ (alhydrogel) is a novel immunotherapy for early alzheimer’s disease. The compound has been used as an adjuvant in human and animal vaccination programs. It has demonstrated significantly slower decline in hippocampal volume as a biomarker.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 15, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
SCB-2019 antigen, a stabilized trimeric form of the S-protein based on the original strain of the SARS-CoV-2 virus, and combined it with Dynavax’s CpG 1018 advanced adjuvant and aluminum hydroxide (alum). Clover is developing it as a universal booster for COVID-19.
Lead Product(s): SCB-2019,Aluminium Hydroxide
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Approved FDFProduct Type: Vaccine
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 14, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : SCB-2019,Aluminium Hydroxide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Clover Launches COVID-19 Booster Vaccine in the People’s Republic of China
Details : SCB-2019 antigen, a stabilized trimeric form of the S-protein based on the original strain of the SARS-CoV-2 virus, and combined it with Dynavax’s CpG 1018 advanced adjuvant and aluminum hydroxide (alum). Clover is developing it as a universal booster ...
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
February 14, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
SCB-2019 antigen, a stabilized trimeric form of the S-protein based on the original strain of the SARS-CoV-2 virus, and combined it with Dynavax’s CpG 1018 advanced adjuvant and aluminum hydroxide (alum). Clover is developing it as a universal booster for COVID-19.
Lead Product(s): SCB-2019,Aluminium Hydroxide
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Approved FDFProduct Type: Vaccine
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 15, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : SCB-2019,Aluminium Hydroxide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Clover Provides Updates on COVID-19 Vaccine Commercial Launch and Strategic Priorities in 2023
Details : SCB-2019 antigen, a stabilized trimeric form of the S-protein based on the original strain of the SARS-CoV-2 virus, and combined it with Dynavax’s CpG 1018 advanced adjuvant and aluminum hydroxide (alum). Clover is developing it as a universal booster ...
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
January 15, 2023

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Regulatory Info : Withdrawn
Registration Country : Malta
Aluminium Hydroxide; Magnesium Hydroxide
Brand Name : Maalox Aluminium Hydroxide/Magnesium Hydroxide For Stomach Relief Berry Oral
Dosage Form : Oral Suspension
Dosage Strength : 460MG; 400MG
Packaging :
Approval Date : 2014-03-17
Application Number :
Regulatory Info : Withdrawn
Registration Country : Malta
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Regulatory Info : Withdrawn
Registration Country : Malta
Magnesium Hydroxide; Aluminium Hydroxide
Brand Name : Maalox Stomach Ache Aluminium Hydroxide/ Magnesium Hydroxide
Dosage Form : Oral Suspension
Dosage Strength : 400MG; 460MG
Packaging :
Approval Date : 2020-04-22
Application Number :
Regulatory Info : Withdrawn
Registration Country : Malta
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Regulatory Info : Cancelled
Registration Country : Spain
Magnesium Hydroxide; Aluminum Hydroxide
Brand Name : Maalox
Dosage Form : Chewable Tablet
Dosage Strength : 400MG; 400 MG
Packaging :
Approval Date : 05-06-2017
Application Number : 82114
Regulatory Info : Cancelled
Registration Country : Spain
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Regulatory Info : Cancelled
Registration Country : Spain
Magnesium Hydroxide; Aluminum Hydroxide
Brand Name : Maalox
Dosage Form : Oral Suspension In Envelope
Dosage Strength : 460MG; 400 MG
Packaging :
Approval Date : 05-06-2017
Application Number : 82113
Regulatory Info : Cancelled
Registration Country : Spain
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Cancelled
Registration Country : Spain
Calcium Carbonate; Magnesium Trisilicate; Aluminum Hydroxide; Glycinate Dihydroxyalumin
Brand Name : Secrepat Forte Oral Suspension Mint Flavor
Dosage Form : Oral Suspension
Dosage Strength :
Packaging :
Approval Date : 10-05-2007
Application Number : 68784
Regulatory Info : Cancelled
Registration Country : Spain

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Marketed
Registration Country : Norway
Aluminum hydroxide; Magnesium hydroxide; Magnesium subcarbonate
Brand Name : Novaluzide
Dosage Form : Chewable Tablet
Dosage Strength :
Packaging :
Approval Date :
Application Number :
Regulatory Info : Marketed
Registration Country : Norway

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Approved
Registration Country : Sweden
Alumina, Hydrated; Calcium Carbonate; Sodium Alginate; Sodium Bicarbonate
Brand Name : Gaviscon
Dosage Form : Oral Suspension
Dosage Strength :
Packaging :
Approval Date : 05-02-1982
Application Number : 1.98E+13
Regulatory Info : Approved
Registration Country : Sweden

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Prescription
Registration Country : Estonia
Aluminium hydroxide; Magnesium hydroxide
Brand Name : Maalox (Suhkruvaba)
Dosage Form : Chewable Tablet
Dosage Strength : 400mg; 400mg
Packaging :
Approval Date :
Application Number :
Regulatory Info : Prescription
Registration Country : Estonia

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info :
Registration Country : Moldova
Aluminum hydroxide; Magnesium hydroxide; Simethicone
Brand Name : Simalgel
Dosage Form : Oral Suspension
Dosage Strength : 405mg/5ml; 100mg/5ml; 125mg/5ml
Packaging :
Approval Date : 03-02-2025
Application Number :
Regulatory Info :
Registration Country : Moldova

Regulatory Info : Allowed
Registration Country : Switzerland
Aluminum Hydroxide; Magnesium Hydroxide
Brand Name : Alucol Peppermint Flavor
Dosage Form : Gel
Dosage Strength :
Packaging :
Approval Date : 14/08/1978
Application Number : 36355
Regulatory Info : Allowed
Registration Country : Switzerland

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Related Excipient Companies
Excipients by Applications
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
58
PharmaCompass offers a list of Aluminium Hydroxide API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Aluminium Hydroxide manufacturer or Aluminium Hydroxide supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Aluminium Hydroxide manufacturer or Aluminium Hydroxide supplier.
A Aluminum hydroxide, dried manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Aluminum hydroxide, dried, including repackagers and relabelers. The FDA regulates Aluminum hydroxide, dried manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Aluminum hydroxide, dried API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Aluminum hydroxide, dried manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.
A Aluminum hydroxide, dried supplier is an individual or a company that provides Aluminum hydroxide, dried active pharmaceutical ingredient (API) or Aluminum hydroxide, dried finished formulations upon request. The Aluminum hydroxide, dried suppliers may include Aluminum hydroxide, dried API manufacturers, exporters, distributors and traders.
click here to find a list of Aluminum hydroxide, dried suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.
A Aluminum hydroxide, dried DMF (Drug Master File) is a document detailing the whole manufacturing process of Aluminum hydroxide, dried active pharmaceutical ingredient (API) in detail. Different forms of Aluminum hydroxide, dried DMFs exist exist since differing nations have different regulations, such as Aluminum hydroxide, dried USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Aluminum hydroxide, dried DMF submitted to regulatory agencies in the US is known as a USDMF. Aluminum hydroxide, dried USDMF includes data on Aluminum hydroxide, dried's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Aluminum hydroxide, dried USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Aluminum hydroxide, dried suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Aluminum hydroxide, dried Drug Master File in Japan (Aluminum hydroxide, dried JDMF) empowers Aluminum hydroxide, dried API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Aluminum hydroxide, dried JDMF during the approval evaluation for pharmaceutical products. At the time of Aluminum hydroxide, dried JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Aluminum hydroxide, dried suppliers with JDMF on PharmaCompass.
A Aluminum hydroxide, dried written confirmation (Aluminum hydroxide, dried WC) is an official document issued by a regulatory agency to a Aluminum hydroxide, dried manufacturer, verifying that the manufacturing facility of a Aluminum hydroxide, dried active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Aluminum hydroxide, dried APIs or Aluminum hydroxide, dried finished pharmaceutical products to another nation, regulatory agencies frequently require a Aluminum hydroxide, dried WC (written confirmation) as part of the regulatory process.
click here to find a list of Aluminum hydroxide, dried suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Aluminum hydroxide, dried as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Aluminum hydroxide, dried API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Aluminum hydroxide, dried as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Aluminum hydroxide, dried and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Aluminum hydroxide, dried NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Aluminum hydroxide, dried suppliers with NDC on PharmaCompass.
Aluminum hydroxide, dried Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Aluminum hydroxide, dried GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Aluminum hydroxide, dried GMP manufacturer or Aluminum hydroxide, dried GMP API supplier for your needs.
A Aluminum hydroxide, dried CoA (Certificate of Analysis) is a formal document that attests to Aluminum hydroxide, dried's compliance with Aluminum hydroxide, dried specifications and serves as a tool for batch-level quality control.
Aluminum hydroxide, dried CoA mostly includes findings from lab analyses of a specific batch. For each Aluminum hydroxide, dried CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Aluminum hydroxide, dried may be tested according to a variety of international standards, such as European Pharmacopoeia (Aluminum hydroxide, dried EP), Aluminum hydroxide, dried JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Aluminum hydroxide, dried USP).